Sanders Morris Harris’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sanders Morris Harris’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,000	Closed	-$226K	–	97
2026 Q1	$226K	Buy	+4,000	New	+$233K	0.04%	256
2025 Q4	–	Sell	-4,000	Closed	-$217K	–	65
2025 Q3	$217K	Buy	+4,000	New	+$229K	0.03%	266
2025 Q2	–	Sell	-4,000	Closed	-$272K	–	179
2025 Q1	$272K	Hold	4,000	–	–	0.04%	221
2024 Q4	$263K	Hold	4,000	–	–	0.04%	239
2024 Q3	$281K	Hold	4,000	–	–	0.05%	221
2024 Q2	$329K	Hold	4,000	–	–	0.05%	202
2024 Q1	$349K	Hold	4,000	–	–	0.06%	193
2023 Q4	$396K	Hold	4,000	–	–	0.19%	131
2023 Q3	$346K	Hold	4,000	–	–	0.07%	181
2023 Q2	$344K	Buy	+4,000	New	+$376K	0.08%	179
2023 Q1	–	Sell	-4,000	Closed	-$414K	–	155
2022 Q4	$414K	Hold	4,000	–	–	0.16%	129
2022 Q3	$347K	Hold	4,000	–	–	0.09%	178
2022 Q2	$340K	Hold	4,000	–	–	0.07%	189
2022 Q1	$308K	Hold	4,000	–	–	0.06%	220
2021 Q4	$354K	Hold	4,000	–	–	0.06%	215
2021 Q3	$311K	Hold	4,000	–	–	0.06%	232
2021 Q2	$338K	Hold	4,000	–	–	0.07%	232
2021 Q1	$312K	Hold	4,000	–	–	0.07%	221
2020 Q4	$328K	Hold	4,000	–	–	0.07%	215
2020 Q3	$320K	Buy	4,000 +250	+7%	+$25.3K	0.09%	198
2020 Q2	$472K	Buy	+3,750	New	+$373K	0.23%	57

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Sanders Morris Harris's BMRN Position: Q2 2026 in Review

Sanders Morris Harris sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 4,000 shares — an estimated $226K sold.

Sanders Morris Harris first reported a position in BMRN in Q2 2020 and held it in 21 quarters. The position peaked at $472K in Q2 2020. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Sanders Morris Harris reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Sanders Morris Harris sold 4,000 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $226K.
Sanders Morris Harris first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 21 quarters.
Sanders Morris Harris's BioMarin Pharmaceuticals position peaked at $472K in Q2 2020.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Sanders Morris Harris's 13F filing for Q2 2026, filed 7 Jul 2026.